Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes

References

• Diekema DJ, Jones RN. Oxazolidinone antibiotics. The Lancet. 2001 Dec 8;358(9297):1975–1982.
   PubMed Web of Science ®Google Scholar
• Morata L, Tornero E, Martinez-Pastor JC, et al. Clinical experience with linezolid for the treatment of orthopaedic implant infections. J Antimicrob Chemother. 2014 Aug 18;69(suppl 1):i47–i52.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos II, Papagelopoulos PJ, et al. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents. 2007 Mar;29(3):233–239.
   PubMed Web of Science ®Google Scholar
• Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev Anti Infect Ther. 2016 Sep 12;14(10):901–915.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antimicrobial resistance global report on surveillance: 2014 summary. Geneva: WHO Press, World Health Organization; 2014. ISBN: 978 92 4 156474 8.
   Google Scholar
• U.S. Department of Health and Human Services. Antibiotic resistance threats in the United States, 2013. Atlanta (GA): Centers for Disease Control and Prevention; 2013.
   Google Scholar
• European Center for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015. ISBN 978-92 9193 729 5.
   Google Scholar
• Monnet DL, Giesecke J. Public health need versus sales of antibacterial agents active against multidrug-resistant bacteria: a historical perspective. J Antimicrob Chemother. 2014 Mar 17;69(4):1151–1153.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. 2014 Financial report. Pfizer Inc. and subsidiary companies; 2015 Mar 10:1–123
   Google Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42(13):1129–1140.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003 Jun 1;47(6):1824–1831.
   PubMed Web of Science ®Google Scholar
• Adverse Event FDA. Reporting System (FAERS). Freedom of Information Act (FOIA). Detailed report: Linezolid.2016
   Google Scholar
• adrreports.eu [Internet]. London: European medicines agency [ cited 2017 Feb 7]. Available from: http://adrreports.eu
   Google Scholar
• Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006 Mar 28;50(4):1599–1602.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012 Jul 11;67(8):2034–2042.
   PubMed Web of Science ®Google Scholar
• Im JH, Baek JH, Kwon HY, et al. Incidence and risk factors of linezolid-induced lactic acidosis. Int Dis. Int Soc Infect Dis. 2015 Feb;1(31):47–52.
   Web of Science ®Google Scholar
• Garrabou G, Soriano A, Lopez S, et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother. 2007 Feb 21;51(3):962–967.
   PubMed Web of Science ®Google Scholar
• Beekmann SE, Gilbert DN, Polgreen PM. Toxicity of extended courses of linezolid: results of an infectious diseases society of America emerging infections network survey. Diagn Microbiol Infect Dis. 2008 Dec;62(4):407–410.
   PubMed Web of Science ®Google Scholar
• Thorell EA, Sharma M, Jackson MA, et al. Disseminated nontuberculous mycobacterial infections in sickle cell anemia patients. J Pediatr Hematol Oncol. 2006 Oct;28(10):678–681.
   PubMed Web of Science ®Google Scholar
• Su E, Crowley K, Carcillo JA, et al. Linezolid and lactic acidosis. Pediatr Infect Dis J. 2011 Sep;30(9):804–806.
   PubMed Web of Science ®Google Scholar
• Rose PC, Hallbauer UM, Seddon JA, et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis. 2012 Dec 1;16(12):1588–1593.
   PubMed Web of Science ®Google Scholar
• Ozkaya-Parlakay A, Kara A, Celik M, et al. Early lactic acidosis associated with linezolid therapy in paediatric patients. Int J Antimicrob Agents. 2014 Oct 1;44(4):334–336.
   PubMed Web of Science ®Google Scholar
• Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med. 2003 Jan 2;348(1):86–87.
   PubMed Web of Science ®Google Scholar
• Palenzuela L, Hahn NM, Nelson RP, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis. 2005 Jun 15;40(12):e113–6.
   PubMed Web of Science ®Google Scholar
• Soriano A, Miró O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med. 2005 Nov 24;353(21):2305–2306.
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006 Apr 15;42(8):1111–1117.
   PubMed Web of Science ®Google Scholar
• Pea F, Scudeller L, Lugano M, et al. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis. 2006 Feb 1;42(3):434–435.
   PubMed Web of Science ®Google Scholar
• Carson J, Cerda J, Chae J-H, et al. Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy. 2007 May;27(5):771–774.
   PubMed Web of Science ®Google Scholar
• Wiener M, Guo Y, Patel G, et al. Lactic acidosis after treatment with linezolid. Infection. 2007 Jul 23;35(4):278–281.
   PubMed Web of Science ®Google Scholar
• Scotton P, Fuser R, Torresan S, et al. Early linezolid-associated lactic acidosis in a patient treated for tuberculous spondylodiscitis. Infection. 2008 Jul 19;36(4):387–388.
   PubMed Web of Science ®Google Scholar
• Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis. 2009 Jul 8;37(2):153–154.
   Google Scholar
• Sujata LM, Russell GB, Hire D, et al. Lactic acidosis from linezolid in a hospitalized patient with kidney failure. Inf Dis Clin Pract. 2009 Nov 1;17(6):404–406.
   Google Scholar
• Velez JCQ, Janech MG. A case of lactic acidosis induced by linezolid. Nature publishing group. Nat Rev Nephrol. 2010 Apr 1;6(4):236–242.
   PubMed Web of Science ®Google Scholar
• De Bus L, Depuydt P, Libbrecht L, et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010 Apr 1;6(3):322–326.
   PubMedGoogle Scholar
• Carbajo T, Fenollosa M, Pons R, et al. Lactic acidosis and linezolid-induced pancytopaenia. Nefrologia. 2011;31(1):107–108.
   PubMed Web of Science ®Google Scholar
• Contou D, Fichet J, Grimaldi D, et al. Early life-threatening lactic acidosis following a single infusion of linezolid. Int J Antimicrob Agents Elsevier B.V. 2011 Jul 1;38(1):84–85.
   PubMed Web of Science ®Google Scholar
• Cope TE, McFarland R, Rapid-Onset SA. linezolid-induced lactic acidosis in MELAS. Mitochondrion. 2011 Nov 1;11(6):992–993.
   PubMed Web of Science ®Google Scholar
• Potolidis E, Gousi E, Delios D. Linezolid induced lactic acidosis and hepatic failure. Int J Case Rep Images. 2012;3(12):79–81.
   Google Scholar
• Miyawaki A, Ueda T, Nakao A, et al. Linezolid-induced lactic acidosis followed by severe hypophosphatemia after discontinuation of linezolid. Surg Infect. 2013 Apr;14(2):229–230.
   PubMed Web of Science ®Google Scholar
• Lee YR, Powell N, Bonatti H, et al. Early development of lactic acidosis with short term linezolid treatment in a renal recipient. J Chemother. 2013 Jul 18;20(6):766–767.
   Google Scholar
• Esnault P, Cotte J, Cungi PJ, et al. Linezolid-induced hyperlactatemia in a burn patient. Ann Fr Anesth Reanim. 2013 Sep 1;32(9):e117–8.
   PubMedGoogle Scholar
• Kraleti S, Soultanova I. Pancytopenia and lactic acidosis associated with linezolid use in a patient with empyema. J Ark Med Soc. 2013 Sep;110(4):62–63.
   PubMedGoogle Scholar
• Del Pozo JL, Fernandez-Ros N, Saez E, et al. Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism. Antimicrob Agents Chemother. 2014 Jun 12;58(7):4227–4229.
   PubMed Web of Science ®Google Scholar
• Sawyer AJ, Haley HL, Baty SR, et al. Linezolid-induced lactic acidosis corrected with sustained low-efficiency dialysis: a case report. Am J Kidney Dis. 2014 Sep 1;64(3):457–459.
   PubMed Web of Science ®Google Scholar
• Hsu S-N, Shih M-F, Yang C-W, et al. Severe linezolid-induced lactic acidosis in a cirrhosis patient. Nephrology (Carlton). 2015 Jan;20(1):47–48.
   PubMed Web of Science ®Google Scholar
• Holmaas G, Lærum JH, Schjøtt J. A man in his seventies with a long-term infection and severe acid-base imbalance. Tidsskr Nor Laegeforen. 2014 Feb 11;134(3):315–319.
   PubMedGoogle Scholar
• Johnson PC, Vaduganathan M, Phillips KM, et al. A triad of linezolid toxicity: hypoglycemia, lactic acidosis, and acute pancreatitis. Proc (Bayl Univ Med Cent). 2015 Oct;28(4):466–468.
   PubMedGoogle Scholar
• Gervasoni C, Bergia R, Cozzi V, et al. Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. J Antimicrob Chemother. 2015 Sep 11;70(10):2918–2920.
   PubMed Web of Science ®Google Scholar
• Mendu DR, Fleisher M, McCash SI, et al. D-lactic acidosis mediated neuronal encephalopathy in acute lymphoblastic leukemia patient: an under diagnosis. Clin Chim Acta. 2015 Feb 20;441(C):90–91.
   PubMed Web of Science ®Google Scholar
• Abou Hassan OK, Karnib M, El-Khoury R, et al. Linezolid toxicity and mitochondrial susceptibility: a novel neurological complication in a Lebanese patient. Front Pharmacol. 2016 Sep 20;7(e1003182):86.
   PubMed Web of Science ®Google Scholar
• Zuccarini NS, Yousuf T, Wozniczka D, et al. Lactic acidosis induced by linezolid mimics symptoms of an acute intracranial bleed: a case report and literature review. J Clin Med Res. 2016;8(10):753–756.
   PubMedGoogle Scholar
• Bernard L, Stern R, Lew D. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis. 2003 May 1;36(9):1197.
   PubMed Web of Science ®Google Scholar
• Boutoille D, Grossi O, Depatureaux A, et al. Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis. Eur Med. Eur Fed Intern Med. 2009 Oct 1;20(6):e134–5.
   PubMedGoogle Scholar
• Djibré M, Pham T, Denis M, et al. Fatal lactic acidosis associated with linezolid therapy. Infection. 2014 Oct 19;43(1):125–126.
   PubMed Web of Science ®Google Scholar
• Protti A, Ronchi D, Bassi G, et al. Changes in whole-body oxygen consumption and skeletal muscle mitochondria during linezolid-induced lactic acidosis. Crit Care Med. 2016 Jul;44(7):e579–82.
   PubMed Web of Science ®Google Scholar
• Ur Rehman H. Linezolid-induced lactic acidosis. Eur J Gen Med. 2016;13(2):149–151.
   Web of Science ®Google Scholar
• Wilson DN, Nierhaus KH. The oxazolidinone class of drugs find their orientation on the ribosome. Molecular Cell. 2007 May;26(4):460–462.
   PubMed Web of Science ®Google Scholar
• Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat Rev Micro. 2005 Oct 2;3(11):870–881.
   PubMed Web of Science ®Google Scholar
• Polacek N, Mankin AS. The ribosomal peptidyl transferase center: structure, function, evolution, inhibition. Crit Rev Biochem Mol Biol. 2008 Oct 11;40(5):285–311.
   Web of Science ®Google Scholar
• Laursen BS, Sorensen HP, Mortensen KK, et al. Initiation of protein synthesis in bacteria. Microbiol Mol Biol Rev. 2005 Mar 8;69(1):101–123.
   PubMed Web of Science ®Google Scholar
• Leach KL, Swaney SM, Colca JR, et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007 May;26(3):393–402.
   PubMed Web of Science ®Google Scholar
• Wilson DN, Schluenzen F, Harms JM. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA. 2008 Sep 9;105(36):13339–13344.
   PubMed Web of Science ®Google Scholar
• Ippolito JA, Kanyo ZF, Wang D, et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem. 2008 Jun;51(12):3353–3356.
   PubMed Web of Science ®Google Scholar
• Lin AH, Murray RW, Vidmar TJ, et al. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997 Oct;41(10):2127–2131.
   PubMed Web of Science ®Google Scholar
• Bobkova EV. Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones. J Biol Chem. 2003 Jan 6;278(11):9802–9807.
   PubMed Web of Science ®Google Scholar
• Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis. 2004 Oct 1;39(7):1010–1015.
   PubMed Web of Science ®Google Scholar
• Greber BJ, Bieri P, Leibundgut M, et al. The complete structure of the 55S mammalian mitochondrial ribosome. Science. 2015 Apr 17;348(6232):303–308.
   PubMed Web of Science ®Google Scholar
• Andersson S, Zomorodipour A, Andersson JO. The genome sequence of Rickettsia prowazekii and the origin of mitochondria. Nature. 1998 Nov 12;396(6707):133–140.
   PubMed Web of Science ®Google Scholar
• Beattie DS, Basford RE, Koritz SB. Studies on the biosynthesis of mitochondrial protein components. Biochem. 1966 Mar;5(3):926–930.
   PubMed Web of Science ®Google Scholar
• Sandell S, Löw H, Decken Von Der A. A critical study of amino acid incorporation into protein by isolated liver mitochondria from adult rats. Biochem J. 1967 Aug;104(2):575–585.
   PubMed Web of Science ®Google Scholar
• Rötig A. Human diseases with impaired mitochondrial protein synthesis. Biochim Biophys Acta. 2011 Sep 1;1807(9):1198–1205.
   PubMed Web of Science ®Google Scholar
• Rossignol R, Faustin B, Rocher C, et al. Mitochondrial threshold effects. Biochem J Portland Press Limited. 2003 Mar 15;370(Pt 3):751–762.
   Google Scholar
• Terjung RL. The turnover of cytochrome c in different skeletal-muscle fibre types of the rat. Biochem J. 1979 Mar 15;178(3):569–574.
   PubMed Web of Science ®Google Scholar
• Karunadharma PP, Basisty N, Chiao YA, et al. Respiratory chain protein turnover rates in mice are highly heterogeneous but strikingly conserved across tissues, ages, and treatments. Faseb J. 2015 Jul 31;29(8):3582–3592.
   PubMed Web of Science ®Google Scholar
• Nagiec EE, Wu L, Swaney SM, et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother. 2005 Aug 26;49(9):3896–3902.
   PubMed Web of Science ®Google Scholar
• McKee EE, Ferguson M, Bentley AT, et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother. 2006 May 24;50(6):2042–2049.
   PubMed Web of Science ®Google Scholar
• Moullan N, Mouchiroud L, Wang X, et al. Tetracyclines disturb mitochondrial function across eukaryotic models: a call for caution in biomedical research. Cell Rep. 2015 Mar 17;10(10):1681–1691.
   PubMed Web of Science ®Google Scholar
• Westermann B. Mitochondrial fusion and fission incell life and death. Nature Publishing Group. Nat Rev Mol Cell Biol. 2010 Dec 1;11(12):872–884.
   PubMed Web of Science ®Google Scholar
• Quiros PM, Mottis A, Auwerx J. Mitonuclear communication in homeostasis and stress. Nature Publishing Group. Nat Rev Mol Cell Biol. 2016 Mar 9;17(4):213–226.
   PubMed Web of Science ®Google Scholar
• Diaz F, Barrientos A, Fontanesi F. Evaluation of the mitochondrial respiratory chain and oxidative phosphorylation system using blue native gel electrophoresis. Curr Protoc Hum Genet. 2009 Oct. 63, Chapter 19: Unit19.4.1 - 19.4.12.
   Google Scholar
• Zerbetto E, Vergani L, Dabbeni-Sala F. Quantification of muscle mitochondrial oxidative phosphorylation enzymes via histochemical staining of blue native polyacrylamide gels. Electrophoresis. 1997 Oct;18(11):2059–2064.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Gervasoni C, Cozzi V, et al. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents. 2016 Dec;48(6):728–731.
   PubMed Web of Science ®Google Scholar
• Morata L, De La Calle C, Gómez-Cerquera JM, et al. Risk factors associated with high linezolid trough plasma concentrations. Expert Opin Pharmacother. 2016 May 25;17(9):1183–1187.
   PubMed Web of Science ®Google Scholar
• Song T, Lee M, Jeon H-S, et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine. 2015 Nov 1;2(11):1627–1633.
   PubMed Web of Science ®Google Scholar
• Kloss P, Xiong L, Shinabarger DL, et al. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol. 1999 Nov 19;294(1):93–101.
   PubMed Web of Science ®Google Scholar
• Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant Enterococci. Antimicrob Agents Chemother. 2001 Jul 1;45(7):2154–2156.
   PubMed Web of Science ®Google Scholar
• mtdb.igp.uu.se [Internet]. Uppsala University, Sweden: department of genetics and pathology. Human Mitochondrial Genome Database [ cited 2017 Feb 7]. Available from: http://www.mtdb.igp.uu.se
   Google Scholar
• Wallace DC, Brown MD, Lott MT. Mitochondrial DNA variation in human evolution and disease. Gene. 1999 Sep 30;238(1):211–230.
   PubMed Web of Science ®Google Scholar
• Pacheu-Grau D, Gomez-Duran A, Iglesias E, et al. Mitochondrial antibiograms in personalized medicine. Hum Mol Genet. 2013 Feb 21;22(6):1132–1139.
   PubMed Web of Science ®Google Scholar
• Mitchell SL, Goodloe R, Brown-Gentry K, et al. Characterization of mitochondrial haplogroups in a large population-based sample from the United States. Hum Genet. 2014 Feb 1;133(7):861–868.
   PubMed Web of Science ®Google Scholar
• Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. Jama. 2001 Mar 14;285(10):1291.
   PubMed Web of Science ®Google Scholar
• Kimmoun A, Novy E, Auchet T, et al. Hemodynamic consequences of severe lactic acidosis in shock states: from bench to bedside. Crit Care. 2015;7:1–13.
   Google Scholar
• Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239–245.
   PubMed Web of Science ®Google Scholar
• Cilley RE, Scharenberg AM, Bongiorno PF, et al. Low oxygen delivery produced by anemia, hypoxia, and low cardiac output. J Surg Res. 1991 Nov;51(5):425–433.
   PubMed Web of Science ®Google Scholar
• Ronco JJ, Fenwick JC, Tweeddale MG, et al. Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. Jama. 1993 Oct;270(14):1724–1730.
   PubMed Web of Science ®Google Scholar
• Baud FJ, Borron SW, Bavoux E, et al. Relation between plasma lactate and blood cyanide concentrations in acute cyanide poisoning. Bmj. 1996 Jan 6;312(7022):26–27.
   PubMed Web of Science ®Google Scholar
• Peddy SB, Rigby MR, Shaffner DH. Acute cyanide poisoning. Pediatric Crit Care Med. 2006 Jan;7(1):79–82.
   PubMed Web of Science ®Google Scholar
• Protti A, Russo R, Tagliabue P, et al. Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care. 2010;14(1):R22.
   PubMed Web of Science ®Google Scholar
• Protti A, Lecchi A, Fortunato F, et al. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care Biomed Central Ltd. 2012 Oct 3;16(5):R180.
   Web of Science ®Google Scholar
• Karlsson M, Ehinger JK, Piel S, et al. Changes in energy metabolism due to acute rotenone-induced mitochondrial complex I dysfunction – An in vivo large animal model. Mitochondrion. 2016 Nov 1;31(C):56–62.
   PubMed Web of Science ®Google Scholar
• Snyder JV, Pinsky MR. Oxygen transport in the critically ill. Chicago (IL): Year Book Medical Publishers Inc; 1987.
   Google Scholar
• Cohen RD, Woods HF, Krebs HA. Clinical and biochemical aspects of lactic acidosis. Oxford [England]: Blackwell Scientific Publications; 1976.
   Google Scholar
• Pea F, Cojutti PG, Baraldo M. A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients? Basic Clin Pharmacol Toxicol. 2017 Apr 17. DOI:10.1111/bcpt.12797.
   PubMed Web of Science ®Google Scholar
• Pea F, Cojutti P, Dose L, et al. A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol. 2015 Dec 5;81(2):341–348.
   PubMed Web of Science ®Google Scholar
• Santini A, Ronchi D, Piga D, et al. The drug induced mitochondrial toxicity book. 2nd ed. New York (NY): Wiley; Forthcoming 2017.
   Google Scholar
• Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis. 2015 Sep 25;61(8):1315–1321.
   PubMed Web of Science ®Google Scholar
• Flanagan S, McKee EE, Das D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2014 Dec 23;59(1):178–185.
   PubMed Web of Science ®Google Scholar
• accessdata.fda.gov [Internet]. U.S. Food and drug administration. Center for drug evaluation and research. Clinical Review NDA 205435 and 205436 SIVEXTRO (Tedizolid phosphate). [ cited 2017 Apr 20]. Available from: https://www.accessdata.fda.gov
   Google Scholar
• Slomovitz BM, Lavery RF, Tortella BJ, et al. Validation of a hand-held lactate device in determination of blood lactate in critically injured patients. Crit Care Med. 1998 Sep;26(9):1523–1528.
   PubMed Web of Science ®Google Scholar
• Oudemans-Van Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy–heparin or citrate? Crit Care. Biomed Central. 2011 Jan 24;15(1):202.
   Google Scholar
• Manthous CA, Hall JB, Kushner R, et al. The effect of mechanical ventilation on oxygen consumption in critically ill patients. Am J Respir Crit Care Med. 1995 Jan;151(1):210–214.
   PubMed Web of Science ®Google Scholar
• Manthous CA, Hall JB, Olson D, et al. Effect of cooling on oxygen consumption in febrile critically ill patients. Am J Respir Crit Care Med. 1995 Jan;151(1):10–14.
   PubMed Web of Science ®Google Scholar
• Cerutti R, Pirinen E, Lamperti C, et al. NAD+-dependent activation of Sirt1 corrects the phenotype
in a mouse model of mitochondrial disease. Cell Metab. 2014 Jun 3;19(6):1042–1049.
   PubMed Web of Science ®Google Scholar
• Goldberg EL, Romero-Aleshire MJ, Renkema KR, et al. Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms. Aging Cell. 2015 Nov 26;14(1):130–138.
   PubMed Web of Science ®Google Scholar
• Vecchio S, Protti A. Metformin-induced lactic acidosis: no one left behind. Crit Care. 2011;15(1):107.
   PubMed Web of Science ®Google Scholar